OKUR

+ Watchlist + Portfolio

OnKure Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.08
52-Week Range: $2.23 – $5.38
Market Cap: $159.15M
P/E (TTM): —
EPS (TTM): -3.03
Dividend Yield: —

Advanced Metrics

Price/Book: 0.92
PEG Ratio: —
Return on Equity: -46.91%
Return on Assets: -29.26%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 26.75
Debt/Equity: 0.01
Total Debt: $926.00K
Free Cash Flow: $-27.11M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-10.24M

OKUR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$25.86M	$32.12M	$43.80M	$48.26M
Selling, General & Admin	$3.90M	$4.82M	$10.59M	$14.69M
Operating Expenses	$29.77M	$36.93M	$54.39M	$62.95M
Operating Income	-$29.77M	-$36.93M	-$54.39M	-$62.95M
EBITDA	-$29.38M	-$34.75M	-$51.71M	-$58.68M
Pretax Income	-$29.51M	-$35.31M	-$52.67M	-$59.52M
Net Income	-$29.51M	-$35.31M	-$52.67M	-$59.52M
Diluted EPS	-2.21	-2.65	-15.28	-4.40
Diluted Shares	13.34M	13.34M	3.45M	13.52M

OKUR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.54M	$29.88M	$110.76M	$59.05M
Current Assets	$13.62M	$33.77M	$113.00M	$60.84M
Total Assets	$16.00M	$35.73M	$114.91M	$62.12M
Current Liabilities	$5.54M	$7.29M	$10.53M	$5.92M
Total Debt	$637.00K	$674.00K	$1.08M	$549.00K
Total Liabilities	$70.42M	$137.58M	$11.08M	$5.93M
Retained Earnings	-$57.07M	-$102.05M	-$154.72M	-$214.24M
Shareholders' Equity	-$54.42M	-$101.84M	$103.83M	$56.18M
Working Capital	$8.08M	$26.48M	$102.47M	$54.92M

OKUR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$26.95M	-$34.55M	-$51.12M	-$51.83M
Capital Expenditure	-$1.13M	-$246.00K	-$52.00K	-$46.00K
Free Cash Flow	-$28.09M	-$34.79M	-$51.17M	-$51.87M
Depreciation & Amortisation	$387.00K	$560.00K	$662.00K	$830.00K
Stock-Based Compensation	$48.00K	$199.00K	$4.53M	$11.63M
Investing Cash Flow	-$1.13M	-$246.00K	$15.87M	-$46.00K
Financing Cash Flow	$26.46M	$53.13M	$116.13M	$163.00K
Net Change in Cash	-$1.62M	$18.33M	$80.89M	-$51.71M

OKUR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.01M	$12.61M	$11.91M	$10.72M	$11.71M
Selling, General & Admin	$3.99M	$3.71M	$3.59M	$3.40M	$3.91M
Operating Expenses	$17.00M	$16.32M	$15.50M	$14.13M	$15.62M
Operating Income	-$17.00M	-$16.32M	-$15.50M	-$14.13M	-$15.62M
EBITDA	-$16.79M	-$15.18M	-$14.49M	-$13.29M	-$15.41M
Pretax Income	-$15.93M	-$15.39M	-$14.70M	-$13.50M	-$15.16M
Net Income	-$15.93M	-$15.39M	-$14.70M	-$13.50M	-$15.16M
Diluted EPS	-1.19	-1.14	-1.09	-0.99	-1.11
Diluted Shares	13.42M	13.51M	13.53M	13.60M	13.67M

OKUR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$96.66M	$83.37M	$70.33M	$59.05M	$192.11M
Current Assets	$98.17M	$84.55M	$71.53M	$60.84M	$197.48M
Total Assets	$99.88M	$86.07M	$72.83M	$62.12M	$198.69M
Current Liabilities	$8.79M	$7.60M	$6.25M	$5.92M	$14.33M
Total Debt	$955.00K	$823.00K	$687.00K	$549.00K	$409.00K
Total Liabilities	$9.23M	$7.90M	$6.41M	$5.93M	$14.34M
Retained Earnings	-$170.65M	-$186.04M	-$200.74M	-$214.24M	-$229.40M
Shareholders' Equity	$90.65M	$78.17M	$66.43M	$56.18M	$184.35M
Working Capital	$89.39M	$76.95M	$65.28M	$54.92M	$183.15M

OKUR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$14.01M	-$13.27M	-$13.04M	-$11.51M	-$12.94M
Capital Expenditure	-$18.00K	-$13.00K	-$6.00K	-$9.00K	-$5.00K
Free Cash Flow	-$14.02M	-$13.29M	-$13.04M	-$11.52M	-$12.94M
Depreciation & Amortisation	$212.00K	$212.00K	$204.00K	$202.00K	$203.00K
Stock-Based Compensation	$2.75M	$2.91M	$2.96M	$3.02M	$2.78M
Investing Cash Flow	-$18.00K	-$13.00K	-$6.00K	-$9.00K	-$5.00K
Financing Cash Flow	-$77.00K	$0.00	$0.00	$240.00K	$146.00M
Net Change in Cash	-$14.10M	-$13.29M	-$13.04M	-$11.28M	$133.06M

Market Snapshot

About

OnKure Therapeutics, Inc. is a precision oncology company developing targeted cancer therapies. The company focuses on novel small molecule inhibitors designed to address critical oncogenic drivers and resistance mechanisms in various tumor types.